Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1752-1947
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series ; volume:12 ; number:1 ; day:3 ; month:6 ; year:2018 ; pages:1-6 ; date:12.2018
Journal of medical case reports ; 12, Heft 1 (3.6.2018), 1-6, 12.2018
- Creator
-
Talotta, Rossella
- Contributor
-
Atzeni, Fabiola
Batticciotto, Alberto
Ditto, Maria Chiara
Gerardi, Maria Chiara
Sarzi-Puttini, Piercarlo
SpringerLink (Online service)
- DOI
-
10.1186/s13256-018-1687-y
- URN
-
urn:nbn:de:101:1-2018080516125688246409
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Talotta, Rossella
- Atzeni, Fabiola
- Batticciotto, Alberto
- Ditto, Maria Chiara
- Gerardi, Maria Chiara
- Sarzi-Puttini, Piercarlo
- SpringerLink (Online service)
Other Objects (12)
Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab
Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
Tocilizumab: A Review in Rheumatoid Arthritis
Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis
Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study
Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
Accelerated diastolic dysfunction in premenopausal women with rheumatoid arthritis
Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis
Efficacy of subcutaneous tocilizumab in patients with rheumatoid arthritis and systemic sclerosis overlap syndrome: a report of two cases and review of the literature
Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT
Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab
Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
Tocilizumab: A Review in Rheumatoid Arthritis
Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis
Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study
Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
Accelerated diastolic dysfunction in premenopausal women with rheumatoid arthritis
Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis
Efficacy of subcutaneous tocilizumab in patients with rheumatoid arthritis and systemic sclerosis overlap syndrome: a report of two cases and review of the literature
Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT
Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab
Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
Tocilizumab: A Review in Rheumatoid Arthritis
Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis
Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study
Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
Accelerated diastolic dysfunction in premenopausal women with rheumatoid arthritis
Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis
Efficacy of subcutaneous tocilizumab in patients with rheumatoid arthritis and systemic sclerosis overlap syndrome: a report of two cases and review of the literature